88IV - PR Newswire Asia's news - Biotechnology

< Previous page

| Title only | Print

Next page >

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026 Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI ... 2026-05-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet CHENGDU, China , May 31, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study ... 2026-05-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet CHENGDU, China , May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinical Oncology ... 2026-05-30T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO CHENGDU, China , May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) ... 2026-05-30T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies BOSTON , May 29, 2026 /PRNewswire/ -- XtalPi (2228.HK), an AI- and robotics- powered drug discovery platform, announced that its strategic collaboration with innovative biopharmaceutical company ... 2026-05-29T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions SHANGHAI , May 29, 2026 /PRNewswire/ -- Innogen (HKEX: 2591), a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for metabolic diseases, ... 2026-05-29T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Holmusk Expands NeuroBlu to 46 Million Patients, Adding Depth and Biomarker Data Across Neurology and Behavioral Health Expansion anchored by two top neurological health systems, structured AD biomarker data, and validated outcomes measures across neurological disease areas. Whole-population ingestion shifts NeuroBlu from ... 2026-05-29T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund SK bioscience's board approval follows the Financial Services Commission's May 28 announcement selecting the company as a beneficiary of the KRW 300 billion (approximately USD 230 million) Korea Growth ... 2026-05-29T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Doctors at Omotesando Helene Clinic Publish New Study on Long-Term Safety Surveillance Following High-Dose Intravenous MSC Administration Continuing clinical data analysis and academic publication in regenerative medicine and ATMP as the Tokyo clinical hub within Helene Bio Group ... 2026-05-29T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines SAN FRANCISCO and NEW YORK, and SUZHOU, China , May 29, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic ... 2026-05-29T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved